Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System

14 de septiembre de 2026 actualizado por: Medacta USA

Randomized, Controlled, Multi-center, Prospective Trial to Assess the Efficacy and Safety of an Anatomic Total Shoulder System.

This study is designed to show that the clinical performance of Mirror Anatomic Shoulder Prosthesis meets the performance of currently marketed device in terms of a composite success endpoint (functional score, radiologic appearance, revisions, adverse events) at 24 months of follow up.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

286

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Emily Hord, CCRP
  • Número de teléfono: 629-333-8860
  • Correo electrónico: ehord@medacta.us.com

Ubicaciones de estudio

  • Estados Unidos
    • Arizona
      • Gilbert, Arizona, Estados Unidos, 85297
        • OrthoArizona
        • Contacto:
        • Investigador principal:
          • Austin Smith, MD
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33428
        • West Boca Medical Center
        • Investigador principal:
          • Jonathan Levy, MD
        • Contacto:
      • Gulf Breeze, Florida, Estados Unidos, 32561
      • Tampa, Florida, Estados Unidos, 33607
        • Foundation for Orthopedic Research and Education
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Kevin Cronin, MD
    • Indiana
      • Fishers, Indiana, Estados Unidos, 46037
        • Central Indiana Orthopedics
        • Investigador principal:
          • Brian Badman, MD
    • Maryland
      • Columbia, Maryland, Estados Unidos, 21044
        • Johns Hopkins - Washington
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Umasuthan Srikumaran, MD
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
    • New York
      • New York, New York, Estados Unidos, 10021
        • Cornell Med NY
        • Contacto:
        • Investigador principal:
          • Theodore Blaine, MD
    • Oregon
      • Medford, Oregon, Estados Unidos, 97504
    • Pennsylvania
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
      • St. George, Utah, Estados Unidos, 84790
        • Intermountain Health
        • Contacto:
        • Investigador principal:
          • Zachary Leitze, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Adult subject 22 years or older
  • Clinical indication for total shoulder replacement due to osteoarthritis, and/or post-traumatic arthritis.
  • Scapula and proximal humerus must have reached skeletal maturity
  • Willing and able to comply with the protocol
  • Willing and able to sign the informed consent (or the Legally Authorized Representative will sign for the subject)

Exclusion Criteria:

  • Lack of sufficient bone quality that in the Investigator's medical judgment could compromise implant fixation or bone healing, including conditions such as:
  • Rapid joint destruction, marked bone loss or bone resorption;
  • Destruction of the proximal humerus that precludes rigid fixation of the humeral component; and
  • Osteomalacia
  • osteoporosis
  • rheumatoid arthritis
  • Metal allergies or sensitivity, including a known allergic reaction to implant metals (e.g., nickel) or polyethylene
  • Patient presents with a malunion or non-union of the tuberosities of the proximal humerus.
  • Infection at or near the site of implantation, including:
  • Glenohumeral joint infection
  • Osteomyelitis
  • Distant or systemic infection
  • Medical conditions or balance impairments that could lead to falls
  • Prior Total, or Reverse Total Shoulder arthroplasty in the affected shoulder.
  • Prior failed rotator cuff surgery, but excluding successful shoulder arthroscopy
  • Any full thickness rotator cuff tear at the time of surgery or a nonfunctional rotator cuff
  • Excessive glenoid bone loss defined by preoperative computed tomography (CT) scans of the shoulder which show insufficient glenoid bone, or insufficient bone identified at the time of surgery
  • Metabolic disorders which may impair bone function
  • Nonfunctional deltoid muscle
  • Neuromuscular compromise condition of the shoulder (e.g., neuropathic joints or brachioplexus injury with a flail shoulder joint)
  • Patients diagnosed with severe shoulder instability
  • Patients diagnosed with subscapularis incompetence
  • Known active metastatic or neoplastic diseases, Paget's disease or Charcot's disease
  • Currently, or within the last 6 months, or planning to be on chemotherapy or radiation
  • Currently taking > 5mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3 months prior to surgery or patients presenting with symptoms of chronic steroid use. (oral steroids for a chronic condition for 12 months prior to and including the date of surgery)
  • Female subjects who are pregnant or planning to become pregnant within the study period
  • In the surgeon's opinion, the subject is unable to understand the study or be compliant with the follow up or have a history of non-compliance with medical advice
  • History of any cognitive or mental health status that would interfere with study participation
  • Substance Use Disorder (alcohol and/or drug)
  • Engages in manual labor or sports activities that could affect shoulder outcome
  • Patients who have a work-related injury leading to shoulder OA
  • Currently enrolled in any clinical research study that might interfere with the current study endpoints
  • Patients with a life expectancy of less than three years
  • Medical condition or balance impairment that could lead to falls
  • Weight bearing shoulder due to wheelchair, crutches, rollator at the time of operation
  • Individuals who are incarcerated or detained in a correctional facility or under any form of legal supervision that limits their ability to voluntarily consent to participate in the trial.
  • Previous randomization of the subject in the current study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: 143 undergoing implantation of the Mirror Anatomic Shoulder Prosthesis (investigational)
Dispositivo: Mirror Anatomic Total Shoulder Prosthesis
Total shoulder arthroplasty is a well-established procedure to treat glenohumeral osteoarthritis (OA), which is usually associated with chronic pain of varying severity, as well as loss of motion and function. To reduce polyethylene wear, a new Shoulder System, mirroring the materials at the humeral/glenoid interface.
Comparador activo: 143 patients undergoing implantation of Medacta Anatomic Shoulder (control)
Dispositivo: Medacta Anatomic Shoulder
Total shoulder arthroplasty is a well-established procedure to treat glenohumeral osteoarthritis (OA), which is usually associated with chronic pain of varying severity, as well as loss of motion and function.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
This study is designed to show that the clinical performance of Mirror Anatomic Shoulder Prosthesis is non-inferior to the performance of currently marketed devices in terms of a composite success endpoint
Periodo de tiempo: 24 months of follow up
The primary endpoint is clinical success, that will be determined if the following 4 criteria are met: No device-related serious adverse event have occurred, ASES score improved more than the Minimally Clinical Important Difference and is at least "fair", No radiological signs of implant subsidence, loosening or progressive radiolucency observed in the humeral or glenoid compartment, as defined in the Radiographic Evaluation Protocol, No revisions, removals, reoperations, or supplemental fixations.
24 months of follow up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Secondary objectives include the assessment of shoulder-specific function and overall health-related quality of life over time using validated patient-reported outcome measures.
Periodo de tiempo: 24 Months of follow up
The secondary endpoint at 24 months will be determined at the 6-week, 6-month, and 1-year timepoints. Radiographic evaluation and assessment, a 100-point patient-reported scale used to evaluate shoulder pain and daily function, 12 questions used to measure general physical/mental health from a patient's perspective (This is evaluated 0-100), Implant survival, and Adverse Events.
24 Months of follow up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Medacta USA

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

11 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de septiembre de 2026

Publicado por primera vez (Actual)

10 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MUSA-MIRROR1-2026

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

Undetermined at this time.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir